“We thought that’s probably the one that’s least likely to pop up,” Geisbert says. “We guessed wrong.”
Concerned by that knowledge gap, in 2011 he decided to modify a vaccine, which led to the crab-eating macaque study. In the same study, he also finally tested a blend of existing ebola vaccines on the Bundibugyo strain, but they didn’t provide 100-percent protection.
If the 2012 outbreak had occurred after the major Zaire outbreak, Geisbert says, it’s possible pharmaceutical companies might’ve been more keen to commercialize a vaccine that protects against the Bundibugyo strain.
But with the present outbreak rivaling the 2013 to 2016 one in terms of scale and scope, efforts to play catch-up are going into high gear. Geisbert suspects WHO’s experience with Ervebo is one of the reasons they favor his vaccine candidate, which is basically “Bundibugyo Ervebo,” he…




